N-[[2-formyl-4-t-butoxycarbonyl]phenyl]-L-aspartic acid β-methyl ester | 171050-09-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[[2-formyl-4-t-butoxycarbonyl]phenyl]-L-aspartic acid β-methyl ester
• 英文别名: (2S)-2-[2-formyl-4-[(2-methylpropan-2-yl)oxycarbonyl]anilino]-4-methoxy-4-oxobutanoic acid
• CAS: 171050-09-2
• 化学式: C₁₇H₂₁NO₇
• 分子量: 351.356
• InChiKey: CQNMSKDJCGOGCA-ZDUSSCGKSA-N

物化性质

• 沸点：
  565.3±50.0 °C(Predicted)
• 密度：
  1.289±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-[[2-formyl-4-t-butoxycarbonyl]phenyl]-L-aspartic acid β-methyl ester 在 platinum(IV) oxide 氢气 、 magnesium sulfate 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 溶剂黄146 、 乙酸乙酯 为溶剂， 生成 (S)-2-methoxycarbonylmethyl-4-methyl-3-exo-2,3,4,5-tetrahydro-1H-benzo-[e][1,4]diazepine-7-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  An alternate enantiospecific synthesis of methyl (S)-7-tert-butoxycarbonyl-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetate

  摘要：

  An alternate enantiospecific synthesis of methyl (S)-7-tert-butoxycarbonyl-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetate (5) is reported. The key step, which involves an intermolecular displacement of the activated aryl fluoride (9) by L-aspartic acid beta-methyl ester, proceeds without racemization. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)00570-4
• 作为产物：
  描述：

  3-氰基-4-氟苯甲酸 在 Raney/Ni 吡啶 、 三氟甲磺酸 、 水 、 氢气 、 碳酸氢钠 、 溶剂黄146 作用下， 以 乙醚 、 水 、 二甲基亚砜 为溶剂， 反应 24.0h， 生成 N-[[2-formyl-4-t-butoxycarbonyl]phenyl]-L-aspartic acid β-methyl ester
  参考文献：
  名称：

  An alternate enantiospecific synthesis of methyl (S)-7-tert-butoxycarbonyl-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetate

  摘要：

  An alternate enantiospecific synthesis of methyl (S)-7-tert-butoxycarbonyl-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetate (5) is reported. The key step, which involves an intermolecular displacement of the activated aryl fluoride (9) by L-aspartic acid beta-methyl ester, proceeds without racemization. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)00570-4

文献信息

• Bicyclic fibrinogen antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US06117866A1

  公开（公告）日：2000-09-12

  Certain compounds within formula (I) are inhibitors of platelet aggregation: ##STR1## wherein A.sup.1 is NH or CH.sub.2 ; R is H, C.sub.1-6 alkyl, benzyl or a carboxy protecting group; R.sup.3 is C.sub.1-6 alkyl, Ar-C.sub.0-6 alkyl, C.sub.3-7 cycloalkylC.sub.0-6 alkyl, or Het-C.sub.0-6 alkyl; R.sup.6 is 4-amidino-Ar-N(CH.sub.3)CO, [[2-(4-piperidinyl)ethyl](N-methyl)amino]carbonyl, (4,4'-bipiperidin-1-yl)carbonyl, [4-(2-aminoethyl)piperidin-1-yl]carbonyl, [[[3-(4-piperidinyl]propyl]methylamino]carbonyl, 1-[4-(4-pyridyl)piperazinyl]carbonyl, [[2-[(2-amino)pyrid-4-yl]ethyl]methylamino]carbonyl, [[2-(4-piperidinyl)ethyl]carbonyl]amino, [[2-(4-piperidinyl)ethyl]carbonyl]amino, [[2-(1-piperazinyl)ethyl]methylamino]-carbonyl, or [[(1,2,3,4-tetrahydro-7-isoquinolinyl]amino]carbonyl; and X is H, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkthio, trifluoroalkyl, N(R').sub.2, CO.sub.2 R', CON(R').sub.2, OH, F, Cl, Br or I.

  化合物(I)中的某些化合物是血小板聚集抑制剂：其中A.sup.1为NH或CH.sub.2；R为H，C.sub.1-6烷基，苄基或羧基保护基；R.sup.3为C.sub.1-6烷基，Ar-C.sub.0-6烷基，C.sub.3-7环烷基C.sub.0-6烷基，或Het-C.sub.0-6烷基；R.sup.6为4-酰胺基-Ar-N(CH.sub.3)CO，[[2-(4-哌啶基)乙基](N-甲基)氨基]羰基，(4,4'-双哌啶-1-基)羰基，[4-(2-氨基乙基)哌啶-1-基]羰基，[[[3-(4-哌啶基]丙基]甲基氨基]羰基，1-[4-(4-吡啶基)哌嗪基]羰基，[[2-[(2-氨基)吡啶-4-基]乙基]甲基氨基]羰基，[[2-(4-哌啶基)乙基]羰基]氨基，[[2-(4-哌啶基)乙基]羰基]氨基，[[2-(1-哌嗪基)乙基]甲基氨基]-羰基，或[[(1,2,3,4-四氢-7-异喹啉基]氨基]羰基；X为H，C.sub.1-4烷基，C.sub.1-4烷氧基，C.sub.1-4烷硫基，三氟甲基，N(R').sub.2，CO.sub.2 R'，CON(R').sub.2，OH，F，Cl，Br或I。
• BICYCLIC FIBRINOGEN ANTAGONISTS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0738150B1

  公开（公告）日：2003-05-02
• US6117866A
  申请人：——

  公开号：US6117866A

  公开（公告）日：2000-09-12
• [EN] BICYCLIC FIBRINOGEN ANTAGONISTS<br/>[FR] ANTAGONISTES DE FIBRINOGENE BICYCLIQUES
  申请人：——

  公开号：WO1995018619A9

  公开（公告）日：2004-10-21

  [EN] Certain compounds within formula (I) are inhibitors of platelet aggregation wherein A<1> is NH or CH<2>; R is H, C1-6alkyl, benzyl or a carboxy protecting group; R<3> is C1-6alkyl, Ar- C0-6alkyl, C1-6cycloalkyl C0-6alkyl, or Het C0-6alkyl; R<6> is 4-amidino-Ar-N(CH3)CO, [[2-(4-piperidinyl)ethyl] (N-methyl)amino] carbonyl, (4,4'-bipiperidin-1-yl) carbonyl, [4-(2-aminoethyl) piperidin-1-yl]carbonyl, [[[3-(4-piperidinyl] propyl]methylamino]carbonyl, 1-[4- (4-pyridyl)piperazinyl]carbonyl, [[2-[(2-amino)pyrid -4-yl]ethyl]methylamino] carbonyl, [[2-(4-piperidinyl) ethyl]carbonyl]amino, [[2-(4-piperidinyl) ethyl]carbonyl]amino, [[2-(1-piperazinyl) ethyl]methylamino] -carbonyl, or [[(1,2,3,4- tetrahydro-7-isoquinolinyl] amino] carbonyl; and X is H, C1-4alkyl, C1-4 alkoxy, C1-4 alkthio, trifluoroalkyl, N(R')2, CO2R', CON(R')2, OH, F, Cl, Br or I.
  [FR] Cette invention se rapporte à certains composés de la formule (I), qui sont des inhibiteurs de l'agrégation plaquettaires. Dans cette formule, A<1 >représente NH ou CH2; R représente H, alkyleC1-6, benzyle ou un groupe protecteur carboxy; R<3> représente alkyleC1-6 Ar- alkyleC0-6, cycloalkyleC3-7, alkyleC0-6, ou Het- alkyleC0-6; R<6> représente 4-amidino-Ar- N(CH3)CO, [[2-(4-pipéridinyl) éthyl](N-méthyl) amino]carbonyle, (4,4'-bipipéridine-1-yl)carbonyle, [4-(2-aminoéthyl) pipéridine-1-yl] carbonyle, [[[3-(4-pipéridinyl]propyl] méthylamino]carbonyle, 1-[4-(4-pyridyl)pipérazinyl] carbonyle, [[2-[(2-amino) pyrid-4-yl]éthyl]méthylamino] carbonyle, [[2-(4-pipéridinyl)éthyl] carbonyl]amino, [[2-(4-pipéridinyl)éthyl] carbonyl]amino, [[2-(1-pipérazinyl) éthyl]méthylamino] -carbonyle, ou [[(1,2,3,4-tétrahydro-7-isoquinolinyl] amino]carbonyle; et X représente H, alkyleC1-4, alcoxyC1-4, alkthioC1-4, trifluoroalkyle, N(R')2, C02R', CON(R')2, OH, F, Cl, Br ou I.
• An alternate enantiospecific synthesis of methyl (S)-7-tert-butoxycarbonyl-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetate
  作者：Thomas W. Ku、Fadia E. Ali、William E. Bondinell、Karl F. Erhard、William F. Huffman、Joseph W. Venslavsky、Catherine C.-K. Yuan

  DOI：10.1016/s0040-4039(97)00570-4

  日期：1997.5

  An alternate enantiospecific synthesis of methyl (S)-7-tert-butoxycarbonyl-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetate (5) is reported. The key step, which involves an intermolecular displacement of the activated aryl fluoride (9) by L-aspartic acid beta-methyl ester, proceeds without racemization. (C) 1997 Elsevier Science Ltd.